CONCLUSIONS AND RELEVANCE These findings suggest that current available immunosuppressive medications, including rituximab, cannot eliminate IgA-secreting plasmablasts/plasma cells, which are likely central to the pathophysiology of IgA-mediated immunobullous diseases. Future studies are needed to develop alternative therapeutic strategies that target autoreactive IgA-secreting plasmablasts/plasma cells.
travenous immunoglobulin (400 mg/kg daily for 5 days), and intravenous pulsed cyclophosphamide (15 mg/kg once monthly for 5 months) were sequentially added to his treatment regimen, again resulting in minimal improvement ( Figure 1A ). Results of peripheral blood CD19 + counts persisted at less than 1%, confirming rituximab activity. Disease progression continued and eventually resulted in worsening oral ulcerations, odynophagia, and significant ocular scarring ( Figure 1B ). The (blue outline) was also detected (25.9%) after treatment ( Figure 2C ). Thus, in our patient, IgA-expressing plasmablasts/ plasma cells were strongly resistant to aggressive immunosuppressive therapy that included B-cell depletion with rituximab.
To gain further insight into the origin of the autoreactive IgA antibodies, the posttreatment perilesional skin biopsy specimen was reevaluated using immunohistochemical analysis for CD19 and CD138, which demonstrated the presence of CD19 + and CD138 + plasmablasts/plasma cells ( Figure 1D ). These immune cells are presumed to contribute to the pathogenic autoreactive IgA antibodies that were detected by direct immunofluorescence ( Figure 1C) . Furthermore, indirect immunofluorescence performed on a normal skin specimen with posttreatment serum using the salt split technique demonstrated IgA reactivity to the epidermal side of the split at a titer of 1:160 (ARUP Laboratories). No IgG was detectable via indirect immunofluorescence.
Discussion
Mei et al 10 recently reported that rituximab fails to deplete selfreplenishing IgA B cells of mucosal origin, although their study lacked patients with IgA-mediated autoimmunity. We speculate that the treatment-resistant peripherally circulating IgAexpressing plasmablasts/plasma cells in our patient are also derived from a self-sufficient population of tissue-resident B cells that are thought to be inherently resistant to anti-CD20 therapy. 10,11 Our patient's MMP did not respond to several additional immunosuppressive medications in addition to rituximab. We therefore hypothesize that his autoreactive IgAsecreting cells are very slowly regenerating or are a long-lived population. Otherwise, they should have been susceptible to the nitrogen mustard-alkylating agent, cyclophosphamide, which is especially toxic to proliferating cells. Also noteworthy was the depletion of B cells longer than 1000 days after rituximab administration in our patient. This duration has been reported rarely in published studies. 12 The patient is now being treated with combination therapy consisting of prednisone, 20 mg/d, leflunomide, 20 mg/d, and dapsone, 100 mg twice daily.
Conclusions
To our knowledge, this report is the first to show that autoreactive IgA-secreting B cells are resistant to multiple immunosuppressive medications, including rituximab. Our study, although limited to a single case, may explain why MMP resulting from autoreactive IgA and IgG manifests more severe disease when compared with MMP mediated by IgG alone. 2 Future studies are needed to develop therapeutic strategies to target autoreactive rituximab-resistant IgA-expressing plasmablasts/ plasma cells.
